Brief: Nymox Pharmaceutical announces new long-term fexapotide placebo crossover study results
24/08/2016 17:18
Aug 24 (Reuters) - Nymox Pharmaceutical Corp NYMX.O :
* Nymox reports successful new long-term fexapotide placebo
crossover study results: major reduction in incidence of surgery
* Results show there was 82-95 pct reduction in number of
these patients who required surgery after they received
crossover fexapotide in trial
* Has completed and fully financed execution of seven phase
3 U.S. BPH clinical protocols
* Expects to file for approvals in next 1-2 quarters
Source text for Eikon: ID:nGNXNAABTa
Further company coverage: NYMX.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Nymox Pharmaceutical
See all newsBrief: Nymox Says Required To Resubmit Application To DKMA
Brief: Nymox Pharmaceutical Corp Says Terminated Employment Of Christopher R Riley As CFO (June 27)
Brief: Nymox Announces Appointment Of Christopher R. Riley As Chief Financial Officer
Brief: Nymox Appeals Deficiency Letter
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba